

Claims

- [c1] A method for treating herpesviridae virus infections, comprising administering a rabies vaccine to a patient.
- [c2] The method of claim 1, wherein the herpesviridae virus is herpes simplex type 1.
- [c3] The method of claim 1, wherein the herpesviridae virus is herpes simplex type 2.
- [c4] The method of claim 1 wherein the rabies vaccine is selected from the group consisting of human diploid cell vaccine, purified chick embryo cell culture vaccine, rabies vaccine adsorbed vaccine, an inactivated rabies virus vaccine, a beta priopriolactine inactivated rabies virus vaccine, IMOVAX, and equivalent rabies vaccines thereof.
- [c5] The method of claim 1, wherein the vaccine is administered intradermally.
- [c6] The method of claim 1, wherein the vaccine is administered intramuscularly.
- [c7] The method of claim 1, wherein the vaccine is administered on an as needed basis.

- [c8] A method of treating a patient suffering from herpes simplex type 1, comprising administering a beta propiolactone inactivated rabies virus vaccine to the patient on an as needed basis.
- [c9] A method of treating a patient suffering from herpes simplex type 2, comprising administering a beta propiolactone inactivated rabies virus vaccine to the patient on an as needed basis.